Advancing Localised Prostate Cancer Treatment

Prostate cancer is the most common cancer in men, with 55,000 new UK cases annually. Localised cancer (confined to the prostate) often allows for long-term survival.

Guided by the NIHR ProtecT trial, national guidelines recommend active surveillance, surgery, or radiotherapy for lower-risk cases.

This webinar explores three major NIHR trials on optimising treatment:

• Can regular MRI scans improve active surveillance?
• Is targeting only the cancerous prostate area as effective as treating the whole prostate?
• Does removing lymph nodes alongside the prostate benefit high-risk cases?

Hear from leading researchers on what we know—and don’t—about treating localised prostate cancer. Presentations will be followed by a Q&A.

Speakers:

• Archana Gopalakrishnan, Imperial College London
• Richard Bryant, University of Oxford
• Krishna Narahari, University Hospital of Wales